<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027337</url>
  </required_header>
  <id_info>
    <org_study_id>01200707998</org_study_id>
    <nct_id>NCT02027337</nct_id>
  </id_info>
  <brief_title>Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants</brief_title>
  <official_title>The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tyumen State Medical Academy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tyumen State Medical Academy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We investigate parameters of hemocoagulation and lipoperoxidation in women using combined
      oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg
      ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that hormonal contraceptives using increase risk of thrombosis. We conduct
      parameters of hemostasis in women that use combined oral contraceptives with antiandrogenic
      activity for contraception and treatment. Considering relationship between lipoperoxidation
      in platelets and hemostasis we expect that limitation of lipoperoxidation by antioxidants can
      restrict hypercoagulation and decrease risk of thrombosis.

      The purpose of this study is decrease of thrombosis risk in women that use combined oral
      contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone, 30 mcg
      ethinylestradiol/3 mg drospirenone, 35 mcg ethinylestradiol/2mg cyproterone acetate. Half of
      the women of each arm (group) receive only combined oral contraceptives (COC), other women
      receive combined oral contraceptives and antioxidant complex Selmevit.

      The blood tests conduct on 19-21 days of the menstrual cycle before COC use (control group)
      or on 19-21 days of COC use after 1, 3, 6 and 12 cycles.

      Also we investigate subjective tolerability, therapeutic effects, menstrual cycle control and
      adverse effects of COCs in women that have or have no antioxidant complex Selmevit
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Activated recalcification time</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Activated partial thromboplastin time</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Prothrombin time</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in International normalized ratio</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in D-dimer concentration</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Fibrinogen concentration</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Soluble fibrin-monomer complexes concentration</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Platelet aggregation</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Antithrombin III activity</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Reserve plasminogen index</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Erythrocyte Lipoperoxidation products, extractable in heptane and isopropanol</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Malondialdehyde Concentration in Erythrocytes</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Glutathion-S-transferase Activity in Erythrocytes</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Superoxide dismutase Activity in Erythrocytes</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin A and E plasma concentration</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 cycles of 4 weeks (between days 18 and 21 of each cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse effects</measure>
    <time_frame>12 cycles of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective tolerability of contraceptives</measure>
    <time_frame>12 cycles of 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Hyperandrogenism</condition>
  <condition>Menstrual Irregularities</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy women that no use combined oral contraceptives</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mcg EE/3 mg drospirenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mcg EE/3 mg drospirenone and Selmevit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mcg EE/3 mg drospirenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mcg EE/3 mg drospirenone and Selmevit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mcg EE/2mg cyproterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mcg EE/2 mg cyproterone and Selmevit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mcg ethinylestradiol /3 mg drospirenone</intervention_name>
    <description>One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12</description>
    <arm_group_label>20 mcg EE/3 mg drospirenone</arm_group_label>
    <other_name>Yaz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mcg ethinylestradiol/3 mg drospirenone and Selmevit</intervention_name>
    <description>One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.</description>
    <arm_group_label>20 mcg EE/3 mg drospirenone and Selmevit</arm_group_label>
    <other_name>Yaz</other_name>
    <other_name>Selmevit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mcg ethinylestradiol/3 mg drospirenone</intervention_name>
    <description>One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12</description>
    <arm_group_label>30 mcg EE/3 mg drospirenone</arm_group_label>
    <other_name>Yasmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mcg ethinylestradiol/3 mg drospirenone and Selmevit</intervention_name>
    <description>One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.</description>
    <arm_group_label>30 mcg EE/3 mg drospirenone and Selmevit</arm_group_label>
    <other_name>Yasmin</other_name>
    <other_name>Selmevit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>35 mcg ethinylestradiol/2 mg cyproterone</intervention_name>
    <description>1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12</description>
    <arm_group_label>35 mcg EE/2mg cyproterone</arm_group_label>
    <other_name>Diane-35</other_name>
    <other_name>Chloe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>35 mcg ethinylestradiol/2 mg cyproterone and Selmevit</intervention_name>
    <description>One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.</description>
    <arm_group_label>35 mcg EE/2 mg cyproterone and Selmevit</arm_group_label>
    <other_name>Diane-35</other_name>
    <other_name>Chloe</other_name>
    <other_name>Selmevit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-35 years

          -  Absence of contraindications for COC use

          -  Informed voluntary consent for examination

        Exclusion Criteria:

          -  Age younger than 18 and older than 35 years

          -  Refusal or failure to comply with the study protocol

          -  Drug or alcohol dependence

          -  Psychiatric diseases

          -  Severe somatic and allergic diseases

          -  Pregnancy

          -  Malignancies

          -  Taking drugs that affect haemostasis, including hormonal contraceptives during 6
             months before study beginning

          -  Cases of thrombosis among first-line relatives in family history

          -  Contraindications to the COC use under Eligibility Criteria of hormonal contraception
             (WHO, 2012)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatyana N Khvoschina</last_name>
    <email>hvoschina-t@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tyumen State Medical Academy</name>
      <address>
        <city>Tyumen</city>
        <zip>3452</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana N Khvoschina</last_name>
      <email>hvoschina-t@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Tatyana N Khvoschina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>January 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tyumen State Medical Academy</investigator_affiliation>
    <investigator_full_name>Khvoschina Tatyana N.</investigator_full_name>
    <investigator_title>Tyumen State Medical Academy</investigator_title>
  </responsible_party>
  <keyword>combined oral contraceptives</keyword>
  <keyword>drospirenone</keyword>
  <keyword>cyproterone</keyword>
  <keyword>hemostasis</keyword>
  <keyword>antioxidants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone acetate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

